ALNYLAM PHARMACEUTICALS, INC. ALNY

Latest FY: 2025 Healthcare Biotechnology
Market Price $248.86
Market Cap $33.20B
P/E Ratio 106.81
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑65.2% YoY
$3.71B
3-Yr CAGR: 53.0%
Net Income ↑212.8% YoY
$313.75M
Net Margin: 8.4%
Free Cash Flow ↑1,192.7% YoY
$465.38M
FCF Yield: 1.40%
EPS (Diluted) ↑206.9% YoY
$2.33
Basic: $2.39
Return on Equity Efficiency
39.8%
ROA: 6.3%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (ALNY)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $47.2M $-335.2M $-410.1M $-4.79 0.00% $-307.7M $-372.3M
FY 2017 $89.9M +90.7% $89.9M $-490.9M -19.7% $-5.42 -13.2% 0.00% $-382.8M $-487.0M -30.8%
FY 2018 $74.9M -16.7% $73.1M $-761.5M -55.1% $-7.57 -39.7% 0.00% $-562.6M $-689.5M -41.6%
FY 2019 $219.8M +193.4% $194.7M $-886.1M -16.4% $-8.11 -7.1% 0.00% $-278.4M $-418.6M +39.3%
FY 2020 $492.9M +124.3% $408.4M $-858.3M +3.1% $-7.46 +8.0% 0.00% $-615.0M $-685.3M -63.7%
FY 2021 $844.3M +71.3% $701.3M $-852.8M +0.6% $-7.20 +3.5% 0.00% $-641.7M $-718.1M -4.8%
FY 2022 $1,037.4M +22.9% $881.5M $-1,131.2M -32.6% $-9.30 -29.2% 0.00% $-541.3M $-613.3M +14.6%
FY 2023 $1,828.3M +76.2% $1,560.1M $-440.2M +61.1% $-3.52 +62.2% 0.00% $104.2M $41.9M +106.8%
FY 2024 $2,248.2M +23.0% $1,941.7M $-278.2M +36.8% $-2.18 +38.1% 0.00% $-8.3M $-42.6M -201.5%
FY 2025 $3,713.9M +65.2% $3,036.8M $313.7M +212.8% $2.33 +206.9% 0.00% $524.1M $465.4M +1,192.7%
$

Valuation

Market Price $248.86
Market Cap $33.20B
Enterprise Value $31.54B
P/E Ratio 106.81
P/B Ratio 42.10
FCF Yield 1.40%
Dividend Yield N/A
Shares Outstanding 133,512,599
%

Profitability & Margins

Gross Margin 81.77%
Operating Margin 13.51%
Net Margin 8.45%
Return on Equity (ROE) 39.76%
Return on Assets (ROA) 6.32%
Asset Turnover 0.75x
Revenue 3-Yr CAGR 52.98%
🛡️

Financial Health & Liquidity

Current Ratio 2.76
Cash Ratio 1.13
Debt / Equity 0.000
Debt / Assets 0.000
Cash & Equivalents $1.66B
Total Debt N/A
Book Value / Share $5.91
💧

Cash Flow Efficiency

Operating Cash Flow $524.08M
Capital Expenditures (CapEx) $58.70M
Free Cash Flow $465.38M
OCF / Revenue 14.11%
FCF / Revenue 12.53%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $2.33
EPS (Basic) $2.39
Dividends / Share N/A
Book Value / Share $5.91
EPS YoY Growth 206.88%
🏛️

Balance Sheet (FY 2025)

Total Assets $4.97B
Total Liabilities $4.18B
Stockholders' Equity $789.18M
Current Assets $4.05B
Current Liabilities $1.47B